JNJ-64619178 for Cancer

Recruiting at23 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Janssen Research & Development, LLC

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced solid tumors and also to identify the recommended Phase 2 dose(s) (RP2Ds) of JNJ-64619178 for NHL and advanced solid tumors (Part 1) and to confirm the tolerability of JNJ-64619178 in participants with lower risk myelodysplastic syndromes (MDS) (Part 2).

Research Team

Janssen Research & Development, LLC Clinical Trial

Principal Investigator

Janssen Research & Development, LLC

Eligibility Criteria

This trial is for adults with B cell non-Hodgkin lymphoma, solid tumors, or lower risk myelodysplastic syndromes who are in good physical condition (ECOG score of 0-1) and have at least one measurable disease site. Women must test negative for pregnancy and agree not to donate eggs. People can't join if they've had certain recent cancer treatments or stem cell transplants, other cancers within the last 3 years (with some exceptions), known allergies to JNJ-64619178, prior organ transplants, or brain involvement by their cancer.

Inclusion Criteria

I have at least one tumor that can be measured.

I am fully active or restricted in physically strenuous activity but can do light work.

I have B cell non-Hodgkin lymphoma, a solid tumor, or lower risk MDS.

Exclusion Criteria

I had a stem cell transplant from my own cells within the last 9 months or received a transplant from a donor.

I haven't had cancer, except for certain skin cancers or cervical cancer in situ, in the last 3 years.

I have had a solid organ transplant.

Treatment Details

Interventions

• JNJ-64619178 (Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor)

Trial Overview The study is testing JNJ-64619178's highest dose that patients can tolerate without severe side effects in those with advanced cancers. It aims to find the best dose for Phase 2 trials (Part 1) and check its safety in people with less aggressive myelodysplastic syndromes (Part 2).

Participant Groups

Group I: Part 2:Dose Confirmation and Expansion Experimental Treatment 1 Intervention

Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.

Group II: Part 1: Dose escalation and RP2D Selection Experimental Treatment 1 Intervention

Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.

Who Is Running the Clinical Trial?

Janssen Research & Development, LLC

Lead Sponsor

Trials

1,022

Recruited

6,408,000+

Giacomo Salvadore

Janssen Research & Development, LLC

Chief Medical Officer since 2023

MD from the University of Rome, Tor Vergata

Ricardo Attar

Janssen Research & Development, LLC

Chief Executive Officer since 2008

PhD in Molecular Biology from the University of Buenos Aires